Efficacy of tigecycline vs. imipenem in the treatment of experimental Acinetobacter baumannii murine pneumonia

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 29, Issue 5, 2010, Pages 527-531

  Pichardo, C ^a,b   Pachon Ibanez M E ^a,b   Docobo Perez, F ^a,b   Lopez Rojas R ^a,b   Jimenez Mejias M E ^a,b   Garcia Curiel, A ^a,b   Pachon, J ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMIPENEM; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; IN VIVO STUDY; LUNG; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DISEASE MODELS, ANIMAL; FEMALE; IMIPENEM; LUNG; MICE; MICE, INBRED C57BL; MINOCYCLINE; PNEUMONIA, BACTERIAL; STATISTICS, NONPARAMETRIC;

EID: 77952092933     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-010-0890-6     Document Type: Article

References (28)

1. JM Cisneros MJ Reyes J Pachón B Becerril FJ Caballero JL García-Garmendía C Ortiz AR Cobacho 1996 Bacteremia due to Acinetobacter baumannii: Epidemiology, clinical findings, and prognostic features Clin Infect Dis 22 1026 1032 1:STN:280:DyaK28znsl2huw%3D%3D 8783704
2. J Garnacho-Montero C Ortiz-Leyba FJ Jiménez-Jiménez AE Barrero-Almodóvar JL García-Garmendia M Bernabeu-Wittell SL Gallego-Lara J Madrazo-Osuna 2003 Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: A comparison with imipenem-susceptible VAP Clin Infect Dis 36 1111 1118 10.1086/374337 1:CAS:528:DC%2BD3sXksFSgtLY%3D 12715304 (Pubitemid 36549630)
3. F Fernández-Cuenca A Pascual A Ribera J Vila G Bou JM Cisneros J Rodríguez-Baño J Pachón L Martínez-Martínez Grupo de Estudio de Infección Hospitalaria 2004 Diversidad clonal y sensibilidad a los antimicrobianos de Acinetobacter baumannii aislados en hospitales españoles. Estudio multicéntrico nacional: Proyecto GEIH-Ab2000 Enferm Infecc Microbiol Clin 22 5 267 271 10.1157/13059819 15207117 (Pubitemid 38756624)
4. J Vila J Pachón 2008 Therapeutic options for Acinetobacter baumannii infections Expert Opin Pharmacother 9 4 587 599 10.1517/14656566.9.4. 587 1:CAS:528:DC%2BD1cXksF2ru7w%3D 18312160 (Pubitemid 351425386)
5. SK Bouchillon DJ Hoban BM Johnson JL Johnson A Hsiung MJ Dowzicky Tigecycline Evaluation and Surveillance Trial (TEST) Group 2005 In vitro activity of tigecycline against 3989 gram-negative and gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004) Diagn Microbiol Infect Dis 52 3 173 179 10.1016/j.diagmicrobio.2005.06.004 1:CAS:528:DC%2BD2MXos1aitrY%3D 16105561 (Pubitemid 41133542)
6. TR Fritsche HS Sader MG Stilwell MJ Dowzicky RN Jones 2005 Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004) Diagn Microbiol Infect Dis 52 3 195 201 10.1016/j.diagmicrobio.2005.05.003 1:CAS:528:DC%2BD2MXos1ait78%3D 16105564 (Pubitemid 41133545)
7. ME Pachón-Ibáñez ME Jiménez-Mejías C Pichardo AC Llanos J Pachón 2004 Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem Antimicrob Agents Chemother 48 4479 4481 10.1128/AAC.48.11.4479-4481.2004 15504889 (Pubitemid 39434923)
8. JJ Schafer DA Goff KB Stevenson JE Mangino 2007 Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii Pharmacotherapy 27 7 980 987 10.1592/phco.27.7.980 1:CAS:528:DC%2BD2sXot1Gjuro%3D 17594203 (Pubitemid 46986684)
9. MJ Rodríguez-Hernández J Pachón C Pichardo L Cuberos J Ibáñez-Martínez A García-Curiel FJ Caballero I Moreno ME Jiménez-Mejías 2000 Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia J Antimicrob Chemother 45 493 501 10.1093/jac/45.4.493 10747827
10. M Wolff ML Joly-Guillou R Farinotti C Carbon 1999 In vivo efficacies of combinations of β-lactams, β-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model Antimicrob Agents Chemother 43 1406 1411 1:CAS:528:DyaK1MXjs12nsLs%3D 10348761
11. E Bergogne-Bérézin KJ Towner 1996 Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features Clin Microbiol Rev 9 148 165 8964033
12. G Bou G Cerveró MA Domínguez C Quereda J Martínez-Beltrán 2000 Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of β-lactamases J Clin Microbiol 38 3299 3305 1:CAS:528:DC%2BD3cXmvFyhsrc%3D 10970374
13. CJ Henwood T Gatward M Warner D James MW Stockdale RP Spence KJ Towner DM Livermore N Woodford 2002 Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936) J Antimicrob Chemother 49 479 487 10.1093/jac/49.3.479 1:CAS:528: DC%2BD38Xit1Ckt70%3D 11864948
14. 21 and cecropin P1 Antimicrob Agents Chemother 45 994 995 10.1128/AAC.45.3.994-995.2001
15. AK Meagher PG Ambrose TH Grasela EJ Ellis-Grosse 2005 Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent Diagn Microbiol Infect Dis 52 3 165 171 10.1016/j. diagmicrobio.2005.05.006 1:CAS:528:DC%2BD2MXos1aitrk%3D 16105560 (Pubitemid 41133541)
16. G Muralidharan M Micalizzi J Speth D Raible S Troy 2005 Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects Antimicrob Agents Chemother 49 1 220 229 10.1128/AAC.49.1.220-229.2005 1:CAS:528: DC%2BD2MXjvVSitQ%3D%3D 15616299 (Pubitemid 40065796)
17. E Rubinstein D Vaughan 2005 Tigecycline: A novel glycylcycline Drugs 65 10 1317 1336 10.2165/00003495-200565100-00002 1:CAS:528:DC%2BD2MXpsFWks7w%3D 15977966 (Pubitemid 41043889)
18. KA Rodvold MH Gotfried M Cwik JM Korth-Bradley G Dukart EJ Ellis-Grosse 2006 Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose J Antimicrob Chemother 58 6 1221 1229 10.1093/jac/dkl403 1:CAS:528:DC%2BD28Xht1Ogsr7I 17012300 (Pubitemid 44884142)
19. WA Craig 1998 Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1 12 10.1086/516284 1:CAS:528:DyaK1cXltVaqtw%3D%3D 9455502
20. ML van Ogtrop D Andes TJ Stamstad B Conklin WJ Weiss WA Craig O Vesga 2000 In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria Antimicrob Agents Chemother 44 4 943 949 10.1128/AAC.44.4.943-949.2000 10722495 (Pubitemid 30165274)
21. KN Agwuh A MacGowan 2006 Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines J Antimicrob Chemother 58 2 256 265 10.1093/jac/dkl224 1:CAS:528:DC%2BD28Xotl2lsLc%3D 16816396 (Pubitemid 44294934)
22. TL Doan HB Fung D Mehta PF Riska 2006 Tigecycline: A glycylcycline antimicrobial agent Clin Ther 28 8 1079 1106 10.1016/j.clinthera.2006.08.011 1:CAS:528:DC%2BD28XhtVGmsrnP 16982286 Review (Pubitemid 44376809)
23. FS Taccone H Rodriguez-Villalobos D De Backer V De Moor J Deviere JL Vincent F Jacobs 2006 Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline Eur J Clin Microbiol Infect Dis 25 257 260 10.1007/s10096-006-0123-1 1:STN:280:DC%2BD283oslalsw%3D%3D 16572310 (Pubitemid 43800546)
24. KB Anthony NO Fishman DR Linkin LB Gasink PH Edelstein E Lautenbach 2008 Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline Clin Infect Dis 46 567 570 10.1086/526775 18199038 (Pubitemid 351263497)
25. AY Peleg BA Potoski R Rea J Adams J Sethi B Capitano S Husain EJ Kwak SV Bhat DL Paterson 2007 Acinetobacter baumannii bloodstream infection while receiving tigecycline: A cautionary report J Antimicrob Chemother 59 1 128 131 10.1093/jac/dkl441 1:CAS:528:DC%2BD28XhtlChtLzE 17082201 (Pubitemid 46017915)
26. C Betriu I Rodriguez-Avial M Gómez E Culebras F López J Alvarez JJ Picazo Spanish Tigecycline Group 2006 Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study Diagn Microbiol Infect Dis 56 4 437 444 10.1016/j. diagmicrobio.2006.07.005 1:CAS:528:DC%2BD28Xht12rtbvP 16949245 (Pubitemid 44872921)
27. MH Scheetz C Qi JR Warren MJ Postelnick T Zembower A Obias GA Noskin 2007 In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii Antimicrob Agents Chemother 51 5 1621 1626 10.1128/AAC.01099-06 1:CAS:528:DC%2BD2sXlt1yjsrk%3D 17307973 (Pubitemid 46744136)
28. J Vouillamoz P Moreillon M Giddey JM Entenza 2008 In vitro activities of tigecycline combined with other antimicrobials against multiresistant gram-positive and gram-negative pathogens J Antimicrob Chemother 61 371 374 10.1093/jac/dkm459 1:CAS:528:DC%2BD1cXptlGqtQ%3D%3D 18033780